Related references
Note: Only part of the references are listed.Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial
Emmanouil Fokas et al.
JAMA ONCOLOGY (2022)
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Renu R. Bahadoer et al.
LANCET ONCOLOGY (2021)
Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Metaanalysis of Oncological and Operative Outcomes
Joseph C. Kong et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
E. F. Giunta et al.
CANCER TREATMENT REVIEWS (2021)
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial
Thierry Conroy et al.
LANCET ONCOLOGY (2021)
The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response
Chien-Chih Chen et al.
CLINICAL COLORECTAL CANCER (2020)
Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians. Do clinicians know what patients want?
Maxime J. M. van der Valk et al.
EJSO (2020)
Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.
Julio Garcia-Aguilar et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types
Tom van den Ende et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients
Kazuaki Yasui et al.
JOURNAL OF RADIATION RESEARCH (2020)
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial
Maxime J. M. van der Valk et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
Maria C. Riesco-Martinez et al.
CANCERS (2020)
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy
Tsung-Wei Chen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
The prognostic value of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: a systematic review and meta-analysis
Yamei Zhao et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
B. Cisel et al.
ANNALS OF ONCOLOGY (2019)
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Claire Lhuillier et al.
GENOME MEDICINE (2019)
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
Yanhong Deng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The clinical role of the TME in solid cancer
Nicolas A. Giraldo et al.
BRITISH JOURNAL OF CANCER (2019)
Should we favour the use of 5 x 5 preoperative radiation in rectal cancer
Clare Kane et al.
CANCER TREATMENT REVIEWS (2019)
Correlation between tumor microenvironment-associated factors and the efficacy and prognosis of neoadjuvant therapy for rectal cancer
Siyu Zhang et al.
ONCOLOGY LETTERS (2019)
Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B plus (GrzB) cytotoxic T-cells in rectal cancer
Armin Jarosch et al.
ONCOIMMUNOLOGY (2018)
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
Maxime J. M. van der Valk et al.
LANCET (2018)
Macrophages induce “budding” in aggressive human colon cancer subtypes by protease-mediated disruption of tight junctions
Kari Trumpi et al.
Oncotarget (2018)
Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions
Yifan Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer
Campbell S. Roxburgh et al.
ONCOIMMUNOLOGY (2018)
Neoadjuvant rectal score: run with the hare and hunt with the hounds
F. Sclafani et al.
ANNALS OF ONCOLOGY (2018)
Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy
Chih-Yang Huang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
Johan Erlandsson et al.
LANCET ONCOLOGY (2017)
Tumor Microenvironment and Differential Responses to Therapy
Eishu Hirata et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival
Anna Berthel et al.
ONCOIMMUNOLOGY (2017)
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
Tristan A. Barnes et al.
BRITISH JOURNAL OF CANCER (2017)
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Glynne-Jones et al.
ANNALS OF ONCOLOGY (2017)
Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome
Viktor H. Koelzer et al.
ONCOIMMUNOLOGY (2016)
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer
F. Sclafani et al.
ANNALS OF ONCOLOGY (2016)
Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study
K. Bujko et al.
ANNALS OF ONCOLOGY (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer
Carlo Aschele et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
M. J. McCoy et al.
BRITISH JOURNAL OF CANCER (2015)
Macrophages and Therapeutic Resistance in Cancer
Brian Ruffell et al.
CANCER CELL (2015)
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
Carmen J. Allegra et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
Anne J. Breugom et al.
LANCET ONCOLOGY (2015)
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Claus Roedel et al.
LANCET ONCOLOGY (2015)
Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer
Vincenzo Valentini et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients
Maria Napolitano et al.
ONCOTARGET (2015)
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
Carmen J. Allegra et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial
A. J. Breugom et al.
ANNALS OF ONCOLOGY (2015)
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control
R. Glynne-Jones et al.
ANNALS OF ONCOLOGY (2014)
CD8+and FOXP3+Tumor-Infiltrating T Cells Before and After Chemoradiotherapy for Rectal Cancer
Eiji Shinto et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
The intratumoural subsite and relation of CD8+ and FOXP3+ T lymphocytes in colorectal cancer provide important prognostic clues
A. Ling et al.
BRITISH JOURNAL OF CANCER (2014)
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study
Jean-Francois Bosset et al.
LANCET ONCOLOGY (2014)
No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT)
Sainato Aldo et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger et al.
LANCET ONCOLOGY (2013)
Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation?
R. Glynne-Jones et al.
ANNALS OF ONCOLOGY (2012)
Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04
Samuel Y. Ngan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
Jean-Pierre Gerard et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years
Rolf Sauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer
Sofia Edin et al.
PLOS ONE (2012)
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Robert J. Gillies et al.
NATURE REVIEWS CANCER (2012)
Smad4 Inactivation Promotes Malignancy and Drug Resistance of Colon Cancer
Panagiotis Papageorgis et al.
CANCER RESEARCH (2011)
LATE PATIENT-REPORTED TOXICITY AFTER PREOPERATIVE RADIOTHERAPY OR CHEMORADIOTHERAPY IN NONRESECTABLE RECTAL CANCER: RESULTS FROM A RANDOMIZED PHASE III STUDY
Morten Braendengen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial
Willem van Gijn et al.
LANCET ONCOLOGY (2011)
Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer
Koji Yasuda et al.
RADIATION ONCOLOGY (2011)
Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer
Joan N. Kyula et al.
CLINICAL CANCER RESEARCH (2010)
Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620
I. K. Tentes et al.
EXPERIMENTAL CELL RESEARCH (2010)
Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging-Defined, Locally Advanced Rectal Cancer: Grupo Cancer de Recto 3 Study
Carlos Fernandez-Martos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Intratumoral Macrophage Counts Correlate With Tumor Progression in Colorectal Cancer
Jung-Cheng Kang et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer
James D. Harrison et al.
ARCHIVES OF SURGERY (2008)
Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival
Dirk Nagorsen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
High macrophage infiltration along the tumor front correlates with improved survival in colon cancer
Johan Forssell et al.
CLINICAL CANCER RESEARCH (2007)
Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer
K. Bujko et al.
BRITISH JOURNAL OF SURGERY (2006)
Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
R Glynne-Jones et al.
BRITISH JOURNAL OF CANCER (2006)
Adverse effects of preoperative radiation therapy for rectal cancer:: Long-term follow-up of the Swedish rectal cancer trial
H Birgisson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients - A dutch colorectal cancer group study
KCMJ Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Occurrence of second cancers in patients treated with radiotherapy for rectal cancer
H Birgisson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
New insights on cell death from radiation exposure
KM Prise et al.
LANCET ONCOLOGY (2005)
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: Role of maturation status and intratumoral localization
MH Sandel et al.
CLINICAL CANCER RESEARCH (2005)
Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial
CAM Marijnen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance
JT Erler et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
D Arango et al.
BRITISH JOURNAL OF CANCER (2004)
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells
AR Dadabayev et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Share Paper
